Astragaloside IV

Astragaloside IV (AS-IV, CAS 84687-43-4) is a tetracyclic triterpenoid saponin with molecular formula C₄₁H₆₈O₁₄ that exerts immunomodulatory, anti-inflammatory, and antioxidant effects primarily through suppression of NF-κB and MAPK signaling, TLR4/p65 downregulation, and ROS scavenging via SOD upregulation. Preclinical in vitro data show cytotoxic IC₅₀ values of 11.41 µM against A549 lung cancer cells and DPPH radical scavenging IC₅₀ of 43.9–51.7 µM, though no validated human clinical trial data currently exist to establish efficacious supplemental doses.

Origin & History

Astragaloside IV is a cycloartane-type tetracyclic triterpenoid saponin isolated from the dried roots of Astragalus membranaceus (Huangqi), a perennial leguminous herb native to northern and northeastern China, Mongolia, and Siberia. The plant thrives in well-drained, sandy loam soils at elevations between 1,000 and 3,000 meters, typically requiring 3–5 years of cultivation before roots reach harvestable potency. It is one of the most economically and medicinally significant plants in the Chinese Pharmacopoeia, cultivated extensively in Gansu, Shanxi, and Inner Mongolia provinces.

Historical & Cultural Context

Astragalus membranaceus, known as Huangqi ('yellow leader') in Traditional Chinese Medicine, has been documented in the Shennong Bencao Jing (Divine Farmer's Materia Medica, circa 200 CE) as a superior tonic for tonifying the Wei Qi (defensive energy), strengthening the spleen, and promoting wound healing. For over 2,000 years, TCM practitioners have prescribed Huangqi root decoctions to treat chronic fatigue, spontaneous sweating, immunodeficiency, and prolapsed organs, placing it among the most revered adaptogens in East Asian medicine. The root was traditionally prepared as a slow-simmered decoction, often combined with Codonopsis pilosula (Dangshen) or Angelica sinensis (Dong Quai) to enhance qi-tonifying and blood-nourishing effects. The isolation and structural elucidation of astragaloside IV as a discrete molecular entity occurred in the late 20th century, providing a scientific anchor to validate the bioactive basis of centuries of empirical use.

Health Benefits

- **Immunomodulation**: AS-IV modulates innate and adaptive immune responses by suppressing pro-inflammatory cytokines IL-1β, TNF-α, and IL-18, and downregulating TLR4/NF-κB signaling, reducing excessive immune activation in preclinical models.
- **Anti-Inflammatory Activity**: By inhibiting both NF-κB and MAPK (p38, ERK) pathways and blocking ICAM-1/CD11b/CD18-mediated neutrophil adhesion, AS-IV at 20 mg/kg significantly reduces myeloperoxidase activity in endothelial tissue in animal studies.
- **Antioxidant Defense**: AS-IV scavenges reactive oxygen species (ROS), upregulates superoxide dismutase (SOD) expression, inhibits malondialdehyde (MDA) release, and stabilizes mitochondrial membrane potential, collectively reducing oxidative cellular damage.
- **Neuroprotection**: Preclinical studies indicate AS-IV attenuates neuronal apoptosis following brain injury by reducing oxidative stress and inflammatory mediator accumulation in hippocampal and cortical tissue, though human neurological trial data are absent.
- **Antifibrotic Effects**: AS-IV suppresses TGF-β1-driven fibroblast activation and extracellular matrix deposition in hepatic and pulmonary fibrosis models, suggesting potential utility in fibroproliferative conditions pending clinical validation.
- **Antitumor Activity**: In vitro cytotoxicity data demonstrate IC₅₀ values of 11.41 µM against A549 (lung), 36.28 µM against BEL-7402 (hepatocellular), and 45.37 µM against SGC-7901 (gastric) cancer cell lines, with mechanisms likely involving autophagy induction and apoptosis pathway activation.
- **Longevity and Autophagy Modulation**: AS-IV extended lifespan in Caenorhabditis elegans models and has been shown to regulate autophagic flux, reducing cellular senescence markers, though translation to human aging biology remains speculative without clinical trial confirmation.

How It Works

Astragaloside IV inhibits the canonical NF-κB pathway by blocking IκB phosphorylation and preventing nuclear translocation of the p65 subunit, thereby reducing transcription of pro-inflammatory genes encoding IL-1β, TNF-α, IL-18, and ICAM-1. Simultaneously, AS-IV suppresses MAPK cascade activation—specifically p38 and ERK1/2 phosphorylation—which dampens downstream inflammatory gene expression and neutrophil adhesion molecule upregulation (CD11b/CD18). On the antioxidant axis, AS-IV chelates ROS, prevents mitochondrial membrane potential collapse, upregulates SOD enzymatic activity, and inhibits lipid peroxidation end-products such as MDA, collectively protecting against oxidative cell death and pyroptosis. Additional molecular targets include TLR4 surface expression downregulation, modulation of autophagic regulators (Beclin-1, LC3-II), and possible telomerase-activating properties attributed to its aglycone cycloastragenol backbone, which has been studied independently for anti-senescence activity.

Scientific Research

The evidence base for astragaloside IV consists predominantly of in vitro cell-line studies and rodent in vivo models, with no large-scale randomized controlled trials in humans identified in the current literature as of 2024. Preclinical cytotoxicity assays provide IC₅₀ values against multiple cancer cell lines (A549: 11.41 µM; BEL-7402: 36.28 µM; SGC-7901: 45.37 µM), and antioxidant capacity has been quantified as DPPH IC₅₀ of 43.9–51.7 µM and β-glucosidase inhibition IC₅₀ of 9.05–21.20 µM. Invertebrate longevity studies using C. elegans demonstrate statistically significant lifespan extension at defined AS-IV concentrations, offering mechanistic hypothesis generation but limited translational value. The overall evidentiary quality is preclinical, and human pharmacokinetic, safety, and efficacy trials are required before any therapeutic or supplemental claims can be substantiated with clinical confidence.

Clinical Summary

No human randomized controlled trials specifically isolating astragaloside IV as a single intervention with reported sample sizes, effect sizes, or validated endpoints have been identified in the peer-reviewed literature to date. Most clinical-adjacent data derive from studies on Astragalus membranaceus root extracts standardized for total astragaloside content, not pure AS-IV, limiting attribution of specific outcomes to this compound. Preclinical dose-response data (e.g., 20 mg/kg in rodent models) have demonstrated reproducible anti-inflammatory and antioxidant endpoints, but allometric scaling to human doses has not been pharmacologically validated. Confidence in clinical benefit is therefore low, and AS-IV should currently be regarded as a promising preclinical candidate requiring Phase I/II human trial investigation.

Nutritional Profile

Astragaloside IV is a pure isolated triterpenoid saponin compound (C₄₁H₆₈O₁₄, MW 784.97 g/mol) and does not possess a conventional macronutrient or micronutrient profile. Structurally, it consists of a cycloartane triterpenoid aglycone (cycloastragenol) glycosylated with one β-D-xylopyranose and one β-D-glucopyranose sugar unit at the C-3 and C-6 positions, respectively. Within the whole Astragalus root, AS-IV co-exists with over 300 phytochemicals including polysaccharides (astragalans, 20–30% of dry weight), flavonoids (calycosin, formononetin), additional cycloartane saponins (astragalosides I, II), alkaloids, and phenolic acids. Oral bioavailability of AS-IV as an isolated compound is pharmacologically noted to be low due to its high molecular weight and polar glycoside moieties, though specific percentage absorption values have not been fully quantified in human pharmacokinetic studies.

Preparation & Dosage

- **Standardized Root Extract (oral capsule/tablet)**: Astragalus membranaceus extracts standardized to 0.5–1% total astragalosides are the most common commercial form; no validated human dose for isolated AS-IV has been established.
- **Isolated AS-IV Powder (research/analytical grade)**: Appears as a white crystalline powder (MW 784.97 g/mol); used at 10–100 µM concentrations in cell-based assays and 10–50 mg/kg in rodent studies—not directly translatable to human supplementation.
- **Traditional Decoction (Huangqi tea)**: Dried Astragalus root (9–30 g per day) simmered in water for 30–60 minutes; AS-IV yield per gram of root is approximately 2.62 mg under optimized alkaline extraction (24% ammonia, 1:10 w/v, 120-minute soak, 52-minute stirring at 25°C, 150 rpm).
- **Chromatographic Isolation**: High-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC) are standard analytical methods for isolating and quantifying AS-IV from raw root material.
- **Timing Note**: No clinical data exist to recommend specific timing; traditional Huangqi preparations are typically consumed daily as a tonic, often in the morning in TCM practice.
- **Standardization Caveat**: Consumers should verify products specify astragaloside IV content (not merely 'total saponins') and are third-party tested, as AS-IV concentrations vary significantly across Astragalus species and root ages.

Synergy & Pairings

Astragaloside IV from Astragalus membranaceus is traditionally and pharmacologically paired with Astragalus polysaccharides (APS), which modulate macrophage activation via TLR4 and complement receptors, creating complementary immunostimulatory effects through distinct molecular targets within the same botanical source. In TCM formulations, Huangqi is frequently combined with Codonopsis pilosula and Angelica sinensis, where the combined polysaccharide and saponin load is hypothesized to produce additive qi-tonifying and hematopoietic effects, though controlled combination pharmacology studies are lacking. Preliminary research also suggests that co-administration of AS-IV with conventional antioxidants such as vitamin C or quercetin may potentiate ROS scavenging via complementary radical-quenching mechanisms, though no formal synergy studies in humans have been completed.

Safety & Interactions

Astragaloside IV has demonstrated low acute toxicity in preclinical animal models at doses up to 20 mg/kg in rodent studies, with no organ toxicity reported at therapeutic test doses in peer-reviewed preclinical literature; however, a formal human maximum tolerable dose has not been established through clinical trial. No specific drug-drug interactions for isolated AS-IV have been characterized in humans, though theoretical interactions with immunosuppressant drugs (e.g., cyclosporine, tacrolimus) are plausible given AS-IV's immunomodulatory activity, and caution is warranted in transplant patients. Contraindications specific to AS-IV have not been formally delineated; the parent herb Astragalus is traditionally contraindicated in acute infections and excess-pattern conditions in TCM, and individuals with autoimmune conditions should consult a physician before use. No safety data for AS-IV during pregnancy or lactation exist; given the absence of reproductive toxicology data, use is not recommended in these populations until further research is conducted.